Company: SMNR
Filing Date: 2025-03-25
Form Type: PRER14A
Source: 0001013762-25-002297
Chunk: 15

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-25
Form: PRER14A
Chunk 15
---
ORDINARY GENERAL MEETING These Questions and Answers are only summaries of the matters they discuss. They do not contain all of the information that may be important to you. You should read carefully the entire document, including the annexes to this proxy statement.

| Why am I receiving this proxy statement? |     | This proxy statement and the accompanying materials are being sent to you in connection with the solicitation of proxies by the Board, for use at the extraordinary general meeting to be held on [    ], 2025 at [    ], Eastern time, at the offices of US Tiger Securities, Inc. located at 437 Madison Avenue, 27th Floor, New York, NY. This proxy statement summarizes the information that you need to make an informed decision on the proposals to be considered at the extraordinary general meeting.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                          |     | We are a blank check company incorporated as a Cayman Islands exempted company whose business purpose is to affect an initial business combination. On April 11, 2022, we consummated the IPO of 8,250,000 units, inclusive of 750,000 units issued pursuant to the underwriters’ partial exercise of their over-allotment option (the “Public Units”). The Public Units were sold at a purchase price of $10.00 per Public Unit, generating gross proceeds of $82,500,000. Substantially concurrently with the consummation of the IPO, we completed the private placement (the “Private Placement”) of 510,000 units (the “Private Placement Units”) at a purchase price of $10.00 per Private Placement Unit to the Sponsor (including the private placement of 30,000 units as a result of the underwriters’ exercise of their over-allotment option), generating gross proceeds of $5,100,000. On the closing date of the IPO, a total of approximately $84,150,000, comprised of the proceeds from the IPO and proceeds from the Private Placement, was placed in the trust account. On October 11, 2023, in connection with the approval of proposed amendments to the amended and restated memorandum and articles of association of the Company, shareholders holding 3,712,171 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s trust account, leaving 4,537,829 public shares outstanding. On July 10, 2024, in connection with